Navigating Care for Liver Cancer Patients
Targeted Navigation to Achieve Health Equity: Increasing Access to Care, Patient Engagement and Research Participation
This study is trying to learn about the experiences of liver cancer patients to create a better support program that helps them and their families manage their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Trial ID | NCT06260943 on ClinicalTrials.gov |
What this trial studies
This study aims to understand the personal perceptions and experiences of patients with liver cancer to enhance their care. Investigators will gather insights on the needs of these patients and their families, particularly those that have not been addressed in current care practices. The goal is to develop a targeted navigation program that assists participants in managing their diagnosis and treatment journey effectively.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older diagnosed with hepatocellular carcinoma or those involved in the care of such patients.
Not a fit: Patients who are unable to communicate in English or Spanish, or those with significant cognitive impairments, may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the support and resources available to liver cancer patients and their families.
How similar studies have performed: While this approach is innovative in its focus on patient navigation, similar studies have shown promise in improving care for cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HCC Patients: * Enrolled or eligible for enrollment in Unified Prospective Registry and Biorepository of Patients with Chronic Liver Disease or Hepatobiliary Cancers Including Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma. * Diagnosis of hepatocellular carcinoma, confirmed by clinical chart review and International Classification of Diseases, Tenth Revision (ICD-10) C22.0. * Adults, age 18 or older * Able to provide informed consent * All other interviewees: * Advocates who will self-identify as having had HCC. * Others who self-identify as either a caregiver or support person of an HCC patient. Physicians/Licensed Independent Practitioners, Social Workers, Nurse Navigators, and Research Coordinators will all self-identify as being involved in the care of HCC patients. Exclusion Criteria: * Unable to speak Spanish or English * West Haven Grade 2 or higher hepatic encephalopathy19 or other cognitive impairment. * Adults unable or unwilling to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Given that this study is minimal risk and there are no risks to a potential fetus, investigators will not exclude pregnant women; however, no data about pregnancy or their fetus is being collected
Where this trial is running
Miami, Florida
- University of Miami — Miami, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Patricia Jones, MD — University of Miami
- Study coordinator: Gloria Figueroa
- Email: gef44@med.miami.edu
- Phone: (305) 243-0779
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.